Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
N-acetyl Semax Amidate
Overview
N-acetyl Semax Amidate is a modified heptapeptide derivative of adrenocorticotropic hormone (ACTH) fragments, engineered with N-terminal acetylation and C-terminal amidation to enhance metabolic stability and blood-brain barrier penetration. It is believed to modulate brain-derived neurotrophic factor (BDNF) expression, enhance dopaminergic and serotonergic signaling, and improve cognitive performance and stress resilience.
Mechanism of Action
This analog exhibits prolonged activity compared to the parent Semax peptide.
Research Summary & Key Findings
Animal studies have demonstrated enhanced learning, memory consolidation, and neuroprotection in models of ischemia and cognitive deficit, with findings reported in neuroscience journals from the early 2000s. Limited human data exist, primarily from Russian clinical practice, with no large-scale randomized controlled trials published in international peer-reviewed literature. The peptide remains investigational outside Eastern Europe.
Clinical Status
N-acetyl Semax Amidate is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "N-acetyl Semax Amidate"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "N-acetyl Semax Amidate"
Registered interventional and observational studies, including status and phase.
- PubChem: "N-acetyl Semax Amidate"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
InvestigationalA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsNo lawful pathway today
N-acetyl Semax Amidate is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.